Indication intelligence, analysis and sector perception

Capricor Therapeutics (CAPR) 1.96 M share offering priced at $3.10

May 8, 2017 8:55am

Investors Include Cedars-Sinai Medical Center and select Board Members

Capricor Therapeutics (NASDAQ: CAPR), has signed a definitive agreement for the sale of approximately $3.7 million of common stock with certain accredited investors.

The private placement is being led by Cedars-Sinai Medical Center and includes select members of the CAPR's Board of Directors.

The investors have agreed to purchase 1,196,291 shares of common stock at a price of $3.10 per share. Gross proceeds from the private placement are expected to be approximately $3.7 million.

The closing of the offering is expected to take place on or about May 10, 2017.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 31 min ago
RegMed Investors (RMi) Closing Bell: hammered

11 hours 22 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.